NZ626028A - Macrocyclic hepatitis c serine protease inhibitors - Google Patents

Macrocyclic hepatitis c serine protease inhibitors

Info

Publication number
NZ626028A
NZ626028A NZ626028A NZ62602809A NZ626028A NZ 626028 A NZ626028 A NZ 626028A NZ 626028 A NZ626028 A NZ 626028A NZ 62602809 A NZ62602809 A NZ 62602809A NZ 626028 A NZ626028 A NZ 626028A
Authority
NZ
New Zealand
Prior art keywords
formula
protease inhibitors
serine protease
hepatitis
iii
Prior art date
Application number
NZ626028A
Inventor
Ken Engstrom
Dong Liu
David J Grampovnik
Dale J Kempf
Hui-Ju Chen
Yonghua Gai
Keith F Mcdaniel
Yat Sun Or
Tim Grieme
Yiyin Ku
Jason P Shanley
Ahmad Sheikh
Jianzhang Mei
Ying Sun
Sable H Wagaw
Original Assignee
Enanta Pharm Inc
Abbvie Bahamas Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enanta Pharm Inc, Abbvie Bahamas Ltd filed Critical Enanta Pharm Inc
Priority claimed from NZ605550A external-priority patent/NZ605550A/en
Publication of NZ626028A publication Critical patent/NZ626028A/en

Links

Landscapes

  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Disclosed is a method of producing a cyclopropylsulfonyl-quinoxaline-carboxamido-hexadecahydrocyclopropa-pyrrolo-diazacyclopentadecine-carboxamide derivative compound of formula I, or a pharmaceutically acceptable salt thereof, comprising the step of reacting a compound of formula II with a quinoxaline derivative of formula (III), wherein the variables and the structure of formulae (II) and (III) are as shown in the specification. These macrocyclic compounds of formula (I) possess activity against the hepatitis C virus (HCV) and are useful in the treatment of HCV infections.
NZ626028A 2008-09-11 2009-09-10 Macrocyclic hepatitis c serine protease inhibitors NZ626028A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19172508P 2008-09-11 2008-09-11
US20968909P 2009-03-10 2009-03-10
NZ605550A NZ605550A (en) 2008-09-11 2009-09-10 Macrocyclic hepatitis c serine protease inhibitors

Publications (1)

Publication Number Publication Date
NZ626028A true NZ626028A (en) 2015-10-30

Family

ID=55023077

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ626028A NZ626028A (en) 2008-09-11 2009-09-10 Macrocyclic hepatitis c serine protease inhibitors

Country Status (1)

Country Link
NZ (1) NZ626028A (en)

Similar Documents

Publication Publication Date Title
TN2011000014A1 (en) Macrocyclic quinoxaline compounds as hcv ns3 protease inhibitors
MX2009009174A (en) Inhibitors of serine proteases for the treatment of hcv infections.
HK1121440A1 (en) Biphenyl derivatives and their use in treating hepatitis c
MX2009008872A (en) Macrocyclic compounds as hcv ns3 protease inhibitors.
GB0413087D0 (en) Therapeutic compounds
TW200732336A (en) Alyphactic heterocyclic compounds
TW200730533A (en) Inhibitors of serine proteases
GEP20084560B (en) Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of hcv replication
WO2005035525A3 (en) 2-amido-4-aryloxy-1-carbonylpyrrolidine derivatives as inhibitors of serine proteases, particularly hcv ns3-ns4a protease
WO2008002924A3 (en) Quinoxalinyl macrocyclic hepatitis c virus serine protease inhibitors
EA200801381A1 (en) DERIVATIVES OF PYRIMIDINE
HK1166788A1 (en)
BRPI0508867A (en) process for the preparation of macrocyclic compounds
MX2010005262A (en) Quinoxaline-containing compounds as hepatitis c virus inhibitors.
TW200728317A (en) Macrocylic inhibitors of hepatitis C virus
MX2010006209A (en) Quinoxalinyl derivatives.
WO2007143694A3 (en) Macrocyclic oximyl hepatitis c protease inhibitors
WO2008021960A3 (en) Triazolyl macrocyclic hepatitis c serine protease inhibitors
WO2008021956A3 (en) Acylaminoheteroaryl hepatitis c virus protease inhibitors
WO2008019303A3 (en) Pyridazinonyl macrocyclic hepatitis c serine protease inhibitors
WO2008019289A3 (en) Tetrazolyl macrocyclic hepatitis c serine protease inhibitors
WO2008022006A3 (en) Arylalkoxyl hepatitis c virus protease inhibitors
WO2009053828A3 (en) P3 hydroxyamino macrocyclic hepatitis c serine protease inhibitors
MX2010006518A (en) Macrocyclic oximyl hepatitis c serine protease inhibitors.
WO2009076166A3 (en) Oximyl hcv serine protease inhibitors

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 10 SEP 2016 BY AJ PARK

Effective date: 20160414

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 SEP 2017 BY THOMSON REUTERS

Effective date: 20160816

ASS Change of ownership

Owner name: ENANTA PHARMACEUTICALS, INC., NZ

Effective date: 20170316

Owner name: ABBVIE IRELAND UNLIMITED COMPANY, BM

Effective date: 20170316

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 SEP 2018 BY THOMSON REUTERS

Effective date: 20170819

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 SEP 2019 BY THOMSON REUTERS

Effective date: 20180816

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 SEP 2020 BY THOMSON REUTERS

Effective date: 20190817

LAPS Patent lapsed